Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Douglas Miehm is an analyst at RBC Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/18/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | GUD | Buy Now | Knight Therapeutics | — | — | Douglas Miehm42% | $7 → $8 | Maintains | Outperform | Get Alert |
| 03/10/2025 | ONC | Buy Now | Oncolytics Biotech | $261.38 | -98.09% | Douglas Miehm42% | $6 → $5 | Maintains | Outperform | Get Alert |
| 03/10/2025 | ONCY | Buy Now | Oncolytics Biotech | $0.60 | 731.67% | Douglas Miehm42% | $6 → $5 | Maintains | Outperform | Get Alert |
| 02/20/2025 | BLCO | Buy Now | Bausch & Lomb | $15.48 | 16.28% | Douglas Miehm42% | $22 → $18 | Maintains | Outperform | Get Alert |
| 02/20/2025 | BLCO | Buy Now | Bausch & Lomb | $15.48 | 16.28% | Douglas Miehm42% | $22 → $18 | Maintains | Outperform | Get Alert |
| 01/30/2025 | BHC | Buy Now | Bausch Health Companies | $7.01 | 42.65% | Douglas Miehm42% | $11 → $10 | Maintains | Neutral | Get Alert |
| 01/30/2025 | BHC | Buy Now | Bausch Health Companies | $7.01 | 42.65% | Douglas Miehm42% | $11 → $10 | Maintains | Sector Perform | Get Alert |
| 01/29/2025 | BLCO | Buy Now | Bausch & Lomb | $15.48 | 42.12% | Douglas Miehm42% | $23 → $22 | Maintains | Outperform | Get Alert |
| 01/29/2025 | BLCO | Buy Now | Bausch & Lomb | $15.48 | 42.12% | Douglas Miehm42% | $23 → $22 | Maintains | Outperform | Get Alert |
| 01/07/2025 | WELL | Buy Now | WELL Health Technologies | $149.97 | -94.33% | Douglas Miehm42% | $7 → $8.5 | Maintains | Outperform | Get Alert |
| 12/11/2024 | LGND | Buy Now | Ligand Pharmaceuticals | $106.22 | 34.63% | Douglas Miehm42% | $141 → $143 | Maintains | Outperform | Get Alert |
